Abstract
The cooperative osteosarcoma study (COSS) group of the German Society of Pediatric Oncology (GPO) has been conducting adjuvant chemotherapy trials in children and adults with Osteosarcoma (OS) of the extremities since 1977. An outline of chemotherapies used for the different trials is given in Figure 32-1, and the metastases-free survival (MFS) probabilities in Figure 32-2.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Winkler K, Bielack S Semin Orthop 3:48–58, 1988. Chemotherapy of osteosarcoma.
Purfürst C, Beron G, Torggler S, et al. Ergebnisse der Studien COSS-77 und COSS-80 für die adjuvante Chemotherapie bei Osteosarkomen der Extremitäten. Klin Pädiatr 197:233–238, 1985.
Winker K et al. Einfluss des lokalchirurgischen Vorgehens auf die Inzidenz von Metastasen. Z Orthop 124:22–29, 1985.
Goorin A, Perez-Atayde A, Gebhard M, et al. Weekly high-dose methotrexate and doxorubicin for osteosarcoma: The Dana-Faber Cancer Institute/the Children’s Hospital study III. J Clin Oncol 5:1178–1184, 1987.
Makley J, Krailo M, Ertel I, et al. The relationship of various aspects of surgical management to outcome in childhood non-metastatic osteosarcoma: a report from the Children’s Cancer Study Group. J Pediatr Surg 23:146–151, 1988.
Picci, P, Bacci G, Mercuri M, et al. Pathological evaluation of chemotherapy response. Influence of necrosis and surgical margins in the incidence of local recurrence. The Rizzoli Institute experience (abstract). J Cancer Res Clin Oncol 116(Suppl II):1130, 1990.
Ruggieri P, Picci P, Marangolo M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities (OE): preliminary results in 116 patients (pts) treated preoperatively whith methotrexate (MTX) (iv), cis-platinum (CDP) (ia) and adriamycin (ADM) (abstract). Proc Annu Meet Am Soc Clin Oncol 9, 310, 1990.
Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intraveneous cisplatin in addition to systemic doxorubicin, high-dose methotrexate and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer 60:1703–1710, 1990.
Salzer-Kuntschik M, Brand G, Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe 4:135–141, 1983.
Friedmann MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4:482–510, 1972.
Link MP, Goorin MA, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600–1606, 1986.
Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337, 1988.
Maeyama I, Furuse K, Yamawaki S, et al. Evaluation of adjuvant chemotherapy of osteosarcoma with special reference to adriamycin (final report). Gan Kagaku Ryoho 15:3245–3251, 1988.
Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. Cancer 65:2539–2553, 1990.
Delling G, Dreyer T, Heise U, et al. Therapieinduzierte Veränderungen an Osteosarkomen: qualitative und quantitative morphologische Ergebnisse der Therapiestudie COSS-80 und ihre Beziehung zur Prognose. Tumordiagn Ther 11:167–174, 1990.
Knop J, Delling G, Heise U, Winkler K. Scintigraphic evaluation of tumor regression during preoperative chemotherapy of osteosarcoma. Correlation of 99 m Tc-methylene diphosphonate parametric imaging with surgical histopathology. Skelet Radiol 19:165–172, 1990.
Bieling P, Winkler K, Bielack S, et al. Continuous infusion (CI) versus short term infusion (SI) of doxorubicin (DOX) in osteosarcoma (OS). Proc Annu Meet Am Soc Clin Oncol 10:-to-, 1991.
A. Sebille, J. Lacau St-Guily, B. Angelard, A. Sfabenrath. Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer. Cancer 65; 2644–2647 (1990).
G. Bacci, M. Avella, A. Brach Del Prevert et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin Preliminary results. Chemioterapio 7; 138–142 (1988).
Patterson WP, Khojasteh A. Ifosfamide-induced renal tubular defects. Cancer 63:649–651, 1989.
Suarez A, Flamant F, Sommelet D, et al. Renal toxicity of ifosfamide in soft tissue sarcoma patients one year minimum after completion of chemotherapy (SIOP MMT 84 study) (abstract). Proc Annu Meet Am Soc Clin Oncol 9:300, 1990.
Antman K, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7:126–131, 1989.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Winkler, K., Bielack, S.S., Delling, G., Jürgens, H., Kotz, R., Salzer-Kuntschik, M. (1993). Treatment of osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group (COSS). In: Humphrey, G.B., Koops, H.S., Molenaar, W.M., Postma, A. (eds) Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Cancer Treatment and Research, vol 62. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3518-8_32
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3518-8_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6561-7
Online ISBN: 978-1-4615-3518-8
eBook Packages: Springer Book Archive